Weight loss doctor appointments

 
W8MD corporate owned weight loss centers 

Poly-Tech Sleep & insurance Physician Weight Loss Center Philadelphia
1718, Welsh Rd, Philadelphia, PA, 19115

215-676-2334 

Our farthest patient for weight loss comes from Nassau, Bahamas! Testimonials!

Philadelphia weight loss doctor

King of Prussia Weight Loss

Poly-Tech Sleep & W8MD's King Of Prussia Weight Loss Center

987 Old Eagle School Rd, Ste 712, Wayne, PA, 19087 (King of Prussia)

215-676-2334 

Our farthest patient for help losing weight comes from Delaware! Testimonials


New York City Weight Loss

W8MD's NYC medical weight loss & Sleep Clinic at Sleep Medical Associates, PLLC

2003, Bath Avenue, Brooklyn, NY, 11214. 

Lear more about losing weight fast in NYC | Our weight loss doctor NYC

718-946-5500

Our farthest weight loss patient comes from Dallas, Texas! Testimonials

weight loss doctor new york city


Other locations 

W8MD licensed locations

The weight loss center in New Jersey Is closed as of May 2017.

BMI Calculator

Your Weight:
Your Height:

Weight loss tips


FDA Finally Approves Belviq for Weight Loss

After years of rejecting many medications for weight loss despite the country having epidemic proportions of obesity, the FDA finally seems to wake to the reality. Until recently, the FDA board that reviewed weight loss medications had no single bariatrician. Some of the medications that were denied in the past were combination medications where the constituents of the combination were already on the market but FDA managed to deny some of these medications for theoretic concerns. About a year ago, FDA finally had a medical bariatrician join its ranks to sit on the board that reviews weight loss medications. So far, we have seen two new weight loss medications approved. This is a step in the right direction and we hope that the FDA keeps pace with the growing epidemic of Obesity. Here is the information on the new drug, Belviq. Please note that it is going to take a little bit of time for the medication to be available on the market. W8MD intends to be one of the first to start using Belviq for W8Loss as soon as they become available on the market.


FDA approves Belviq

The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for chronic weight management.

The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese), or adults with a BMI of 27 or greater (overweight) and who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).

BMI, which measures body fat based on an individual’s weight and height, is used to define the obesity and overweight categories. According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese.

“Obesity threatens the overall well being of patients and is a major public health concern,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. “The approval of this drug, used responsibly in combination with a healthy diet and lifestyle, provides a treatment option for Americans who are obese or are overweight and have at least one weight-related comorbid condition.”

Belviq works by activating the serotonin 2C receptor in the brain. Activation of this receptor may help a person eat less and feel full after eating smaller amounts of food.

The safety and efficacy of Belviq were evaluated in three randomized, placebo-controlled trials that included nearly 8,000 obese and overweight patients, with and without type 2 diabetes, treated for 52 to 104 weeks. All participants received lifestyle modification that consisted of a reduced calorie diet and exercise counseling. Compared with placebo, treatment with Belviq for up to one year was associated with average weight loss ranging from 3 percent to 3.7 percent.

About 47 percent of patients without type 2 diabetes lost at least 5 percent of their body weight compared with about 23 percent of patients treated with placebo. In people with type 2 diabetes, about 38 percent of patients treated with Belviq and 16 percent treated with placebo lost at least 5 percent of their body weight. Belviq treatment was associated with favorable changes in glycemic control in those with type 2 diabetes. The approved labeling for Belviq recommends that the drug be discontinued in patients who fail to lose 5 percent of their body weight after 12 weeks of treatment, as these patients are unlikely to achieve clinically meaningful weight loss with continued treatment.

Belviq should not be used during pregnancy. Treatment with Belviq may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors. These include, but are not limited to, drugs commonly used to treat depression and migraine. Belviq may also cause disturbances in attention or memory.

In 1997, the weight-loss drugs fenfluramine and dexfenfluramine were withdrawn from the market after evidence emerged that they caused heart valve damage. This effect is assumed to be related to activation of the serotonin 2B receptor on heart tissue. When used at the approved dose of 10 milligrams twice a day, Belviq does not appear to activate the serotonin 2B receptor.

Heart valve function was assessed by echocardiography in nearly 8,000 patients in the Belviq development program. There was no statistically significant difference in the development of FDA-defined valve abnormalities between Belviq and placebo-treated patients. Because preliminary data suggest that the number of serotonin 2B receptors may be increased in patients with congestive heart failure, Belviq should be used with caution in patients with this condition. Belviq has not been studied in patients with serious valvular heart disease.

The drug’s manufacturer will be required to conduct six postmarketing studies, including a long-term cardiovascular outcomes trial to assess the effect of Belviq on the risk for major adverse cardiac events such as heart attack and stroke.

The most common side effects of Belviq in non-diabetic patients are headache, dizziness, fatigue, nausea, dry mouth, and constipation, and in diabetic patients are low blood sugar (hypoglycemia), headache, back pain, cough, and fatigue.

Belviq is manufactured by Arena Pharmaceuticals GmbH of Zofingen, Switzerland, and distributed by Eisai Inc. of Woodcliff Lake, N.J.

Source: US FDA

W8MD weight loss locations for Belviq

Weight loss centers that accept insurance

Pennsylvania
 Philadelphia Insurance Weight Loss & Sleep Center: 1718, Welsh Rd, Philadelphia, PA, 19115 Ph: 1-215-676-2334 

Philadelphia weight loss doctor

King Of Prussia Weight Loss & Sleep Center: 987 Old Eagle School Rd, Ste 712, Wayne, PA, 19087 Ph: 215-676-2334 


 New York

NYC Insurance Weight Loss & Sleep Center: 2003, Bath Avenue, Brooklyn, NY, 11214 Ph: 1-718-946-5500. 

weight loss doctor new york city


 

New Jersey

W8MD medical weight loss program at Vida Sleep Center of Dr. Felix Roque's office at 543, 45th Street, Union City, New Jersey. 543 45th St, Union City, NJ  07087Phone: (201) 766-6469. This center bills out of network for insurance

Cities Served

Philadelphia weight loss centersPhiladelphiaKing Of PrussiaWarminster, Wayne, Norristown, Exton, West Chester, Lansdale, Pottstown, Bensalem, Norriton, Phoenixville, Collegeville, Ardmore, Drexel Hill, Springfield, Lansdale, Darby, Horsham, Willow Grove, Abington, Doylestown, Jenkintown etc.
New Jersey Weight Loss CentersUnion City, Jersey City, West New York
New York Weight Loss Centers Brooklyn, Staten Island, Manhattan, Long Island, West Hempstead, Franklin Square, NY, Hempstead, NY, Garden City, New Hyde Park, Uniondale, North Valley Stream,  New York City, Queens, Bronx, NYC, Bayonne
Counties Served: Philadelphia, Delaware, Chester, Bucks, Montgomery, Burlington, Kings, Richmond, Queens, Manhattan, Bronx, Nassau county NY, Hudson County, NJ

Physicians

Most physicians have nothing to offer their overweight patients other than simply say"Lose Weight!" or hand out a diet sheet.This is not useful for most patients as obesity needs a more thorough and structured approach! Physicians Be A W8MD Weight Loss Doctor

Before And After Weight Loss | Weight Loss Video Testimonials

Disclaimer

W8MD medical weight loss centers of America is designed to provide general information on our insurance physician weight loss program locations, and general weight loss information. W8MD medical weight loss website or any of our affiliated weight loss blogs is not intended to diagnose, treat, cure, or prevent any disease. Also note insurance coverage may vary based on your plan, deductibles, co-insurance etc. and our participation in your plan. Contact your insurance carrier for your coverage details. 

Individual results may vary. No expressed or implied warranties!

Bill of Rights and Health Disclaimer.

1(800)986-3007

(800-W8MD-007)

Think W'eight'MD for weight loss!